Table 1.
Clinical characteristics of the enrolled population
| Clinical characteristics | HC group (n = 29) | HBV group (n = 26) | C. sinensis group (n = 24) | Coinfected group (n = 22) |
|---|---|---|---|---|
| Age (years) | 44.86 ± 7.46 | 42.59 ± 12.21 | 42.42 ± 9.11 | 40.73 ± 10.49 |
| Gender (male/female) | 26/3 | 23/3 | 22/2 | 20/2 |
| HBV DNA (Log copies/ml) | Negative | 4.61 ± 1.91 | Negative | 5.50 ± 1.70 |
| ALT (U/l) | 22.00 (9–73) | 62.50 (20–665)***# | 43.50 (3–615)*### | 233.50 (14–733)*** |
| AST (U/l) | 22.00 (16–45) | 41.50 (21–401)***# | 31.00 (18–191)*### | 148.50 (21–382)*** |
| TB (μmol/l) | 11.00 (2.80–32.64) | 16.30 (6.80–418.00)# | 13.27 (5.00–472.10)## | 51.15 (8.90–626.50)*** |
| HA (ng/ml) | 45.17 (30.00–94.85) | 77.93 (30.00–255.35)**# | 67.88 (30.00–1000.00)*# | 131.20 (30.00–1000.00)*** |
| PCIII (ng/ml) | 7.37 (5.06–10.86) | 11.00 (4.55–26.11)* | 10.59 (1.50–32.39)** | 7.45 (1.50–31.06) |
| LN (ng/ml) | 44.00 (16.23–83.84) | 71.49 (15.00–161.81) | 40.86 (15.00–189.52) | 38.95 (15.00–327.13) |
| COLIV (ng/ml) | 34.10 (15.02–86.39) | 52.74 (21.62–1000.00) | 26.90 (15.00–1000.00) | 72.37 (15.00–671.37) |
Values in table are shown as the mean ± standard error (SE) or as the median with the range in parentheses, with the exception of Gender
ALT Alanine aminotransferase, AST aspartate aminotransferase, COL IV type IV collagen, HA hyaluronic acid, HBV hepatitis B virus, LN laminin, PCIII type III procollagen, TB total bilirubin
Kruskal–Wallis rank test was used for comparison among multiple groups: *P < 0.05, **P < 0.01, ***P < 0.001, vs healthy control (HC) group; #P < 0.05, ##P < 0.01, ###P < 0.001, vs co-infected group